Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Struggling Miners Offset Buoyant Admiral

Wed, 15th Aug 2018 12:02

LONDON (Alliance News) - Reversing some early gains, stocks in London had tumbled firmly into the red by midday on Wednesday with miners falling and apprehension around Turkey remaining.The pound, meanwhile, was trending lower despite UK inflation accelerating for the first time since November last year.The FTSE 100 down 0.8%, or 64.14 points, at 7,547.50 - having hit a high of 7,632.07 in early trade Wednesday. The FTSE 250 was down 0.4%, or 73.60 points, at 20,436.16. The AIM All-Share was 0.2% lower at 1,085.60.In mainland Europe, the CAC 40 in Paris was down 0.4% while the DAX 30 in Frankfurt was down 0.1% at midday. In the US, stocks are pointed to follow Europe with a lower start. The Dow Jones is called down 0.3%, while the S&P 500 and the Nasdaq are seen opening 0.2% lower. Focus in the US on Wednesday is on retail sales at 1330 BST. Before this, at 1200 BST, are MBA mortgage applications."The problem for risk appetite is that the bounce by Turkey's lira largely reflected profits being taken. It was not due to effectiveness of the central bank's piecemeal and relatively small dollar-liquidity moves," said Ken Odeluga, market analyst at City Index.The lira on Monday hit record lows, before steadying on Tuesday but experiencing shaky trade overnight."Turkey's lira lost all Wednesday gains at one point, following Tuesday's bounce of more than 8%. It is now firmer again, though clearly volatile. It's uncertain whether the rebound will be sustained. " added Odeluga.Inflaming the situation, Turkey increased tariffs on US-made products ranging from cars to tobacco on Wednesday. The new measures, published in the official gazette, go into effect immediately and include a 140% hike in US-made alcoholic beverages and an increase of 120% on US cars.In the UK, the pound was lower as the Office for National Statistics on Wednesday showed UK inflation accelerated for the first time in eight months in July.Consumer prices climbed 2.5% year-on-year in July, as expected by economists, but slightly faster than the 2.4% increase in June. Core inflation that excludes energy, food, alcoholic beverages and tobacco, held steady at 1.9% in July.However, analysts expect inflation growth to trail off in the short-term."Barring any further gyrations in oil prices, we think July's figure represents a peak, and we expect CPI to begin trending downwards over the next few months gradually," said James Smith, developed markets economist at ING.Smith continued: "The impact of the pound's post-Brexit plunge is continuing to fade - prices have more-or-less adjusted to the weaker level of sterling - and this is seeing core goods inflation slow. We expect this to keep core CPI close to 2% for the foreseeable future, although there's a risk that this slips lower."Sterling was quoted at USD1.2709 Wednesday midday, having traded around USD1.2729 prior to the release of the data and lower than USD1.2736 at the London equities close on Tuesday.Hindering the FTSE 100 on Wednesday were blue-chip miners, with Antofagasta, Anglo American and Glencore down 3.5%, 3.4% and 3.0%, respectively."The price of copper has this week hit a 13-month low following a sharp slowdown in China's fixed-asset investment growth. This news, together with waning investor appetite for riskier assets, has unsurprisingly put a dent in the mining sector," explained Russ Mould, investment director at AJ Bell."Copper is widely considered to be a bellwether for the global economy and so a weak price is cause for concern," he added.The FTSE 350 Mining Sector Index - which houses many of London's commodity stocks - was down 2.6% at midday.Unable to offset these losses was Admiral's 3.4% rise, as its interim results beat market forecasts.The FTSE 100-listed insurer posted a 9.1% increase in pretax profit to GBP211.0 million from GBP193.4 million the year before. Revenue increased 14% to GBP1.66 billion from GBP1.45 billion.The company is proposing an interim dividend of 60.0 pence per share, a 7.1% increase year-on-year from 56.0p paid the previous year.Chief Executive Officer David Stevens said: "Zut alors. Nos operations europeennes sont rentables! Or probably more accurately, given that over half of our European customers are Italian - le nostre compagnie Europee sono in profitto. Moreover, the European insurers delivered overall profitability whilst growing the business by almost a fifth in a year."The European insurance business - comprising operations in Spain, Italy and France - posted its first ever profit of GBP2.5 million, versus a GBP5 million loss a year ago.GlaxoSmithKline gained 1.5% after the drugmaker said ViiV Healthcare - its HIV treatment joint venture - saw its Atlas study meet its primary endpoint.Phase 3 of the study - for a long-acting, injectable two-drug regimen for the treatment of HIV - showed long-acting cabotegravir and rilpivirine, injected once a month, had similar efficacy to a standard of care, daily, oral three-drug regimen at Week 48.The injectable treatment regimen met the primary endpoint for non-inferiority, Glaxo said. Overall safety, virologic response and drug resistance results for the injectable regimen were consistent with results from the phase II Latte and Latte-2 studies.Sat atop the mid-cap FTSE 250 was Hikma Pharmaceuticals, up 6.3% as it upgraded its revenue guidance for two of its units.Hikma on Wednesday said pretax profit for the six months to the end of June totalled USD141.0 million, up from USD100.0 million reported for the same period a year earlier, as revenue climbed 11% to USD989.0 million from USD895.0 million. Looking ahead, Hikma said it now expects revenue for its Injectables division for 2018 to come in between USD775 million and USD825 million. Previously, Hikma had targeted the unit to achieve revenue in a range of USD750 million to USD800 million.Hikma also now expects the Generics division to deliver revenue in the range of USD600 million to USD650 million, up from the USD550 million to USD600 million range forecast in mid-May.Balfour Beatty, up 2.9%, boosted its interim payout by a third.The construction company multiplied its pretax profit to GBP50 million from just GBP12 million the year before. Revenue decreased 9.4% to GBP3.84 billion from GBP4.20 billion.While revenue fell, the company said, gross profit increased and overheads declined, resulting in improved profitability.Balfour is proposing an interim dividend increase of 33% to 1.6p per share from 1.2p last year.Kaz Minerals was slumped at the bottom of the mid-caps, down 6.7% as the copper miner was dented along with blue-chip peers by tumbling commodity prices.
More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.